One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer 2009 Feb;52(2):259-62
Date
10/22/2008Pubmed ID
18937333Pubmed Central ID
PMC5752113DOI
10.1002/pbc.21757Scopus ID
2-s2.0-59449095901 (requires institutional sign-in at Scopus site) 51 CitationsAbstract
BACKGROUND: We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.
METHODS: Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.
RESULTS: Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention.
CONCLUSIONS: Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%).
Author List
Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ, Pediatric Rituximab/ITP Study Group, Glaser Pediatric Research NetworkAuthor
Thomas Abshire MD Emeritus Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAntibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Child
Child, Preschool
Chronic Disease
Female
Follow-Up Studies
Hemorrhage
Humans
Infant
Male
Platelet Count
Purpura, Thrombocytopenic, Idiopathic
Recurrence
Remission Induction
Rituximab
